Factor VII deficiency is a relatively infrequent hereditary bleeding disorder. Recombinant factor VIIa has been used to treat patients with factor VII deficiency with bleeding episodes or undergoing surgery. The drug has shown a high efficacy rate and will provide factor VII-deficient patients with a therapeutic agent that is not derived from human plasma.